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BACKGROUND: Millions of women receive clinical
breast examination (CBE) each year, as either a breast
cancer screening test or a diagnostic test for breast
symptoms. While screening CBE had moderately high
specificity (∼94%) in clinical trials, community clini-
cians may be comparatively inexperienced and may
conduct relatively brief examinations, resulting in even
higher specificity but lower sensitivity.
OBJECTIVE: To estimate the specificity of screening
and diagnostic CBE in clinical practice and identify
patient factors associated with specificity.
DESIGN: Retrospective cohort study.
SUBJECTS: Breast-cancer-free female health plan
enrollees in 5 states (WA, OR, CA, MA, and MN) who
received CBE (N=1,484).
MEASUREMENTS: Medical charts were abstracted to
ascertain breast cancer risk factors, examination
purpose (screening vs diagnostic), and results (true-
negative vs false-positive). Women were considered
“average-risk” if they had neither a family history of
breast cancer nor a prior breast biopsy and “increased-
risk” otherwise.
RESULTS: Among average- and increased-risk women,
respectively, the specificity (true-negative proportion) of
screening CBE was 99.4% [95% confidence interval (CI):
98.8–99.7%] and 97.1% (95% CI: 95.7–98.0%), and the
specificity of diagnostic CBE was 68.7% (95% CI: 59.7–
76.5%) and 57.1% (95% CI: 51.1–63.0%). The odds of a
true-negative screening CBE (specificity) were signifi-
cantly lower among women at increased risk of breast
cancer (adjusted odds ratio 0.21; 95% CI: 0.10–0.46).
CONCLUSIONS: Screening CBE likely has higher spec-
ificity among community clinicians compared to exam-
iners in clinical trials of breast cancer screening, even
among women at increased breast cancer risk. Highly
specific examinations, however, may have relatively low
sensitivity for breast cancer. Diagnostic CBE, mean-
while, is relatively nonspecific.
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INTRODUCTION
The American Cancer Society recommends that asymptomatic
women over the age 20 years receive regular clinical breast
examinations (CBEs) as screening tests for breast cancer.
1 The
U.S. Preventive Services Task Force recommends screening
mammography with or without CBE for women over 40 years
old.
2 Although national CBE rates have declined slightly with
increasing mammography use,
3 CBE screening is still per-
formed on millions of U.S. women per year.
4 Many others
receive diagnostic CBE to evaluate breast symptoms or
mammographic abnormalities. With limited access to mam-
mography in most developing countries, CBE may be the only
practical means of population-based breast cancer screening
in many parts of the world.
5
An accurate estimate of CBE specificity is critical to judging
the likely effectiveness of CBE in community practice. Rela-
tively high specificity may be associated with low sensitivity,
compromising cancer detection, whereas relatively low speci-
ficity may lead to excessive diagnostic testing and unnecessary
patient anxiety. In clinical trials of breast cancer screening, the
sensitivity and specificity of screening CBE were 54 and 94%,
respectively,
6 but clinical trial results may reflect CBE perfor-
mance under idealized circumstances that differ substantially
from actual clinical practice. Some community-based studies
suggest that CBE sensitivity may be substantially lower in
actual practice than in clinical trials.
7–10 Because sensitivity is
typically inversely related to specificity, relatively lower sensi-
tivity of CBE in the community would suggest that specificity
may be higher. However, community-based studies of screen-
ing CBE specificity have been limited by sampling only low-
income women,
7 women from single U.S. health plans,
11,12 or
women who were examined by specially trained nurses
12 or a
single radiologist.
8
We estimated the specificity of screening and diagnostic CBE
among women enrolled in 6 large U.S. health plans and
determined patient and examination characteristics associated
with specificity. We hypothesized that screening CBE specificity
would be higher in community settings than has been reported
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332in clinical trials because examination duration may be relatively
brief in community practice,
13 leading to a reduced ability to
detect abnormalities.
14 Conversely, we hypothesized that the
specificity of diagnostic CBE would be relatively low because of
patient and clinician concerns about missed breast cancer. We
also hypothesized that specificity of screening CBE would be
lower among women with clinical factors associated with
increased breast cancer risk (e.g., family history of breast
cancer) because clinicians may interpret subtle breast abnor-
malities more cautiously among these women.
METHODS
Setting and Subjects
This study was conducted within the Cancer Research Net-
work, a National Cancer Institute-supported consortium of
nonprofit health maintenance organizations developed to
increase the effectiveness of preventive, curative, and support-
ive interventions that span the natural history of major
cancers among diverse populations and health systems
through a program of collaborative research.
15 The subjects
were female enrollees from 6 large health plans in 5 U.S. states
(WA, OR, CA, MN, and MA) for whom receipt of CBE was
ascertained for a matched case-control study assessing the
effectiveness of breast cancer screening.
16 In the present
study, we analyzed CBE results among the cancer-free control
subjects to estimate CBE specificity. Our study included all
CBEs performed on control subjects greater than 1 year prior
to the date on which they were ascertained to be free of breast
cancer. Thus, the reference standard was the absence of a
cancer diagnosis within 1 year of CBE. CBE outcomes among
the breast cancer cases have been reported separately.
10
Control subjects were matched by age, breast cancer risk,
and health plan enrollment period to cases from the same
health plan who were aged 40–65 years when diagnosed with
breast cancer in 1983–1993 and who subsequently died of
breast cancer. Controls had not been diagnosed with breast
cancer prior to an index date when breast cancer was first
suspected in their matched case. Women were considered to be
at “increased breast cancer risk” if they had a family history of
breast cancer or a personal history of breast biopsy and
“average risk” otherwise.
Receipt of breast cancer testing was ascertained by medical
chart review for 3 years prior to each subject’s index date. For
some cases, the index date (when breast cancer was first
suspected) preceded the breast cancer diagnosis date by up to
2 years, so our sample includes CBEs performed on some
controls when they were younger than 40 years old. We
classified CBEs as “screening” when performed on asymptom-
atic subjects not receiving CBE to evaluate a previous positive
test (e.g., mammography). CBEs performed on women report-
ing breast symptoms or to evaluate previous positive tests were
considered “diagnostic.”
Our study included 1,484 breast-cancer-free women who
received either screening or diagnostic CBE from 1979–1992.
Of these, 1,427 women underwent 2,206 screening examina-
tions, and 177 women received 381 diagnostic examinations. Of
the 1,427 women who received screening CBE, 120 (8.4%) also
received diagnostic CBE. During the study period, each plan
recommended approximately annual CBE screening for women
aged 40 or more years old. Current plan recommendations
either regard CBE as an optional accompaniment to screening
mammography (like the U.S. Preventive Services Task Force) or
make no specific recommendation regarding CBE screening.
Data Abstraction and Quality
The methods of chart abstraction and data quality monitoring
have been described previously.
17 In brief, all abstractors
completed an 8-step training protocol that included the study
of training manuals and mock abstraction of standardized
chart examples that were based on common, potentially
ambiguous clinical situations (e.g., distinguishing screening
from diagnostic tests). Abstractors coded examination results
into 1 of 4 categories based on clinicians’ recorded impressions
and follow-up recommendations: (1) normal, (2) abnormal
benign (e.g., fibrocystic changes not requiring further evalua-
tion), (3) indeterminate (e.g., new abnormality requiring or
diagnostic testing or follow-up), or (4) suspicious for cancer.
To monitor data quality, a second reviewer who was blinded
to subjects’ cancer status randomly reabstracted selected
charts, and interrater reliability of screening and diagnostic
mammography results was excellent (Kappa ranged from 0.76
to 0.91).
17 In addition, 3 clinicians (MBB, SWF, JGE), blinded
to cancer status, reviewed the records of women for whom
coded events might be questionable (e.g., a screening CBE
within 9 months of a prior indeterminate/suspicious screening
CBE) and resolved ambiguities by consensus. Coding
remained unchanged for 93% of those labeled as screening
CBEs and 92% of those labeled as diagnostic CBEs.
Study Variables
Outcome Measures. We defined CBE results as positive if
coded “indeterminate” or “suspicious of cancer” because these
interpretations would prompt follow-up testing or surveillance.
CBE results of “normal” or “abnormal benign” were considered
negative. Among average- and increased-risk women,
respectively, we estimated the specificities of screening and
diagnostic CBE as the proportion of these examinations that
were interpreted as negative.
Independent Variables. The following were determined on the
examination date: age, use of estrogen therapy, and receipt of
Pap smear. We classified a woman as an “estrogen user” if she
received CBE (1) during a period defined by 2 separate chart
notes signifying continuing estrogen use, (2) more than 30 days
after starting estrogen therapy and continuation or discontin-
uation of estrogen was subsequently noted, or (3) within
90 days of an isolated note signifying estrogen continuation.
Women were otherwise classified as “nonusers or uncertain.”
Additional covariates were determined as of each subject’s
index date: family history of breast cancer, including chart
documentation of breast cancer in a first- or second-degree
relative;numberofbreastbiopsies;historyofnaturalorsurgical
menopause; and the Charlson Comorbidity Index
18 modified to
include an additional point for hypertension. We included
measures of Pap smear receipt and hypertension because we
hypothesized that time allotted for Pap tests and hypertension
care could influence CBE duration. A woman was considered
“peri- or postmenopausal” if (1) menopausal status was specif-
333 Fenton et al.: Clinical Breast Examination JGIMically stated in the chart, (2) the woman had undergone surgical
oophorectomy, or (3) symptoms of menopause (e.g., vasomotor
instability, irregular menses) were recorded in the chart without
a specific diagnosis of menopause. Race was also determined
whenever possible from the medical record.
Analyses
We used logistic regression with generalized estimating equa-
tions (GEE) to estimate 95% confidence intervals (CI) for
specificity estimates, which accounted for dependent out-
comes among women who received more than 1 CBE during
the study period.
19 To identify patient and examination
characteristics associated with specificity, we used logistic
regression with GEE to model the probability of a true-negative
CBE (specificity) as a function of individual covariates while
adjusting for health plan. Thus, odds ratios (ORs) greater than
1 signify that a covariate is associated with greater specificity.
Independent variables were included in the models as indicator
(dummy) variables. When modeling outcomes of diagnostic
examinations, we included year of examination first as an in-
dicator variable then as a grouped linear parameter to judge
whether the specificity of diagnostic CBE changed linearly over
time. Because several covariates were significantly associated
with specificity of diagnostic CBE (P<0.05), we repeated logistic
regression while including all significant covariates simulta-
neously. Hypothesis tests were 2-sided with an alpha of 0.05.
The study methods were approved by the Institutional Review
Boards of each of the 6 health plans.
RESULTS
Subject Characteristics
The subjects ranged in age from 35 to 65 years, and
approximately one-fifth were nonwhite (Table 1). Over one-
third (34.8%) of women who received screening CBE had either
a family history of breast cancer or a personal history of breast
biopsy and were classified as increased-risk for breast cancer.
Among women who received diagnostic CBE, two-thirds
(65.5%) were considered increased-risk by these criteria. Most
of the 381 diagnostic examinations (75%) were performed to
evaluate breast symptoms. Among women who received
screening CBE, the mean number of examinations per woman
was 1.55 (SD=0.78; range 1–6). The mean number of diagnos-
tic examinations per woman was 2.15 (SD=1.64; range 1–11).
Specificity of CBE
Among 930 average-risk women who received 1,387 screening
CBEs, 9 (0.7%) were interpreted as indeterminate and none
were interpreted as suspicious for cancer (Table 2). Among 497
increased-risk women who received 819 screening CBEs, 23
(2.8%) were indeterminate and 1 (0.1%) was suspicious for
cancer. Thus, the specificities of screening CBE among
average- and increased-risk women, respectively, were 99.4%
(95% CI: 98.8–99.7%) and 97.1% (95% CI: 95.7–98.0%).
Among 61 average-risk women who received 115 diagnostic
CBEs, 36 (31.3%) were indeterminate and none were suspi-
cious for cancer. Among 116 increased-risk women who
received 266 diagnostic CBEs, 100 (37.6%) were indeterminate
Table 1. Patient and Examination Characteristics Among Cancer-
Free Women Receiving Screening or Diagnostic Clinical Breast
Examination
Screening CBE
(N=1,427 women)
(N=2,206 exams
for examination
characteristics)
Diagnostic CBE
(N=177 women)
(N=381 exams for
examination
characteristics)
%( n)% ( n)
Patient characteristics
Age, years*
35–39 11.1 (159) 14.7 (26)
40–44 31.0 (442) 31.1 (55)
45–49 20.6 (294) 27.1 (48)
50–54 11.7 (167) 11.3 (20)
55–59 15.4 (219) 8.5 (15)
60–65 10.2 (146) 7.3 (13)
Race
Black 7.8 (111) 9.0 (16)
White 72.1 (1,029) 75.1 (133)
Other 10.5 (150) 10.7 (19)
Unknown 9.6 (137) 5 (9)
Family history of breast cancer
No 76.4 (1,090) 66.1 (117)
Yes 23.6 (337) 33.9 (60)
Number of prior breast biopsies
None 84.7 (1,208) 55.9 (99)
One 11.1 (159) 22.6 (40)
Two or more 4.2 (60) 21.5 (38)
Menopausal status
Premenopausal 34.1 (486) 37.9 (67)
Peri- or postmenopausal 47.2 (673) 43.5 (77)
Uncertain 18.8 (268) 18.6 (33)
Charlson comorbidity index
‡
0 64.4 (919) 66.1 (117)
1 24.5 (349) 22.0 (39)
>=2 11.1 (159) 11.9 (21)
Examination characteristics
§
Estrogen use on exam date
Estrogen user 13.3 (294) 12.1 (46)
Nonuser or uncertain 86.7 (1,912) 87.9 (335)
Pap smear received on exam date
No 42.0 (926) 91.6 (349)
Yes 58.0 (1,280) 8.4 (32)
Examination year
1979–1982 12.1 (267) 15.2 (58)
1983–1985 30.8 (679) 33.6 (128)
1986–1988 32.7 (722) 31.0 (118)
1989–1992 24.4 (538) 20.2 (77)
Reason for diagnostic examination
Possibly symptomatic NA 10.8 (41)
Clearly symptomatic NA 63.8 (243)
Other positive test NA 25.5 (97)
Data at % (n) or mean (SD) and reflect measurements on date of earliest
CBE unless otherwise noted. Because of rounding, column percents may
not sum to exactly 100.
CBE clinical breast examination.
*Patient age on date of most recent CBE.
‡Modified to include 1 point for hypertension.
§Across all examinations so may include multiple observations per
woman.
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diagnostic CBE were 68.7% (95% CI: 59.7–76.5%) among
average-risk women and 57.1% (95% CI: 51.1–63.0%) among
increased-risk women.
Correlates of Specificity
Table 3 shows the associations between individual patient and
examination characteristics and CBE specificity after adjust-
ment for health plan. Among screening examinations, both a
family history of breast cancer and a history of prior breast
biopsy wereassociatedwith significantly lowerspecificity. Thus,
compared to women at average breast cancer risk, women at
increased risk had significantly reduced odds of true-negative
screening CBE (OR 0.21; 95% CI: 0.10–0.46). Patient age, race,
menopausal status, estrogen use, chronic disease comorbidity,
Pap smear receipt, and examination year were not significantly
associated with screening CBE specificity.
Among women who received diagnostic examination, those
with 2 or more breast biopsies had significantly lower specific-
ity relative to women without prior breast biopsy (OR 0.53;
95% CI: 0.32–0.89). Reduced specificity of diagnostic CBE was
also associated with concurrent estrogen use (OR 0.32; 95%
CI: 0.16–0.61) and later examination year (P for trend=0.03).
However, examination year was no longer significantly associ-
ated with specificity (P for trend=0.27) in a multivariate model
that simultaneously controlled for examination year, concur-
rent estrogen use, number of breast biopsies, and health plan
(data not shown).
DISCUSSION
We found that the screening CBE had very high specificity
(>99%) among female health plan enrollees at average-risk of
breast cancer. Although specificity of screening CBE was lower
among women with increased breast cancer risk, it was still
high (>97%) compared to clinical trials of breast cancer
screening in which screening CBE specificity was approxi-
mately 94%. Diagnostic CBE was relatively nonspecific regard-
less of breast cancer risk.
Although screening CBE is recommended by some organi-
zations and is commonly performed, few studies have reported
screening CBE specificity in community practice. Specificity of
screening CBE was 96.3% among women receiving screening
CBE within a New England health plan that participated in our
study.
11 In contrast, higher specificities were observed among
nurse examiners within a unique screening program within
another participating plan
12 and among screening CBEs
performed by a single radiologist.
8 In our study, screening
CBE had similarly high specificity among a geographically
diverse sample of women enrolled in 6 regional health plans
who received CBE from diverse examiners.
Among a large sample of low-income women receiving
examinations in the National Breast and Cervical Cancer Early
Detection Program (NBCCEDP),
7 the specificity of screening
CBE was lower (96.2%) than among average-risk (99.1%) and
increased-risk women (97.8%) in our study. Many women
eligible to enroll in the NBCCEDP, however, may not have had
recent previous examinations. Because of higher cancer prev-
alence among previously unscreened women, prevalence
screens may have greater sensitivity but lower specificity than
later rounds of screening. Thus, CBE performance among
NBCCEDP enrollees may not generalize to populations receiv-
ing more regular breast cancer screening. In addition, data
quality assessment of NBCCEDP claims may be limited. If a
substantial fraction of enrollees with breast symptoms are mis-
classified as asymptomatic, estimates of screening CBE spec-
ificity based on NBCCEDP claims may be spuriously reduced.
The discrepancy in the specificity of screening CBE in the
community and in clinical trials suggests that CBE conduct in
actual practice may differ substantially from its conduct in
experimental settings. The American Cancer Society recom-
mends regular CBE screening based in part on clinical trial
evidence that CBE can detect some cancers that are missed by
mammography.
20,21 In the trial achieving the highest CBE
sensitivity (69%), trained examiners performed CBE in a
systematic fashion with a usual duration of 5 to 10 minutes.
22
The typical screening CBE in the community is probably less
systematic and briefer,
13 which may compromise sensitivity
while boosting specificity. Indeed, the high specificity observed
in our study is consistent with recent studies suggesting low
sensitivity of screening CBE in community practice.
7–10 Recent
calls to standardize CBE conduct and reporting may be well-
justified if screening CBE performance in community practice
indeed falls short of performance in clinical trials.
23
Specificity of screening CBE was significantly lower among
women at increased risk for breast cancer. Patient history and
perceived risk influence the interpretation of screening mam-
mography.
24 Clinical history may similarly lead clinicians to
interpret subtle breast abnormalities more cautiously among
women with risk factors for breast cancer. Clinicians might
also conduct the examination more deliberately among these
women, thereby increasing the likelihood of detection and
Table 2. Clinical Breast Examination Results by Examination Purpose and Breast Cancer Risk
CBE result, n (%) Screening CBE Diagnostic CBE
Average-risk (930 women,
1,387 examinations)
Increased-risk (497 women,
819 examinations)
Average-risk (61 women,
115 examinations)
Increased-risk (116 women,
266 examinations)
Normal 1,274 (91.9) 685 (83.6) 27 (23.5) 44 (16.5)
Abnormal benign 104 (7.5) 110 (13.4) 52 (45.2) 108 (40.6)
Indeterminate 9 (0.7) 23 (2.8) 36 (31.3) 100 (37.6)
Suspicious for cancer 0 1 (0.1) 0 15 (5.3)
Specificity*, % (95% CI) 99.4 (98.8–99.7) 97.1 (95.7–98.0) 68.7 (59.7–76.5) 57.1 (51.1–63.0)
CBE clinical breast examination, CI confidence interval.
*Specificity defined as the proportion of examinations that were negative (either normal or abnormal benign). Confidence intervals estimated with
generalized estimated equations to account for correlation of examination results within women. Because of rounding, column percents may not sum to
exactly 100.
335 Fenton et al.: Clinical Breast Examination JGIMsubsequent evaluation of small breast lumps. Even so, the
observed specificity of screening CBE among increased-risk
women (97.1%) was still higher than among a general popula-
tion within clinical trials of breast cancer screening (94%).
6
Breast cancer is relatively common among women with
certain breast symptoms,
25 and cancer may be impossible to
exclude based on physical examination alone. In this respect,
the low specificity of diagnostic CBE may reflect good practice.
Diagnostic CBE was significantly less specific among current
estrogen users. This association could arise from estrogen
effects on breast tissue or other characteristics of estrogen
users that prompt further evaluation after diagnostic CBE.
The examinations in our study were performed from 1979 to
1992, and one might posit that current CBEs are of higher
quality. However, we found no evidence of temporal trends in
screening CBE performance and doubt that U.S. clinicians
currently conduct the screening CBE differently. In addition,
we studied a population of insured women aged 35–65 years
with stable health plan enrollment, and our findings may not
be generalizable to women outside this age range or who have
different insurance statuses. Although our sample size is
smaller than previous studies, precise estimates of screening
CBE specificity do not require large samples because false-
positive screens occur uncommonly. We found no significant
Table 3. Association Between Patient and Examination Characteristics and Clinical Breast Examination Specificity
Characteristic Screening CBE (N=1,427 women
who received 2,206 exams)
Diagnostic CBE (N=177 women
who received 381 exams)
OR* 95% CI* OR* 95% CI*
Age on examination date, years
35–39 1.0 (ref) 1.0 (ref)
40–44 0.71 0.15 3.35 1.06 0.54 2.08
45–49 0.46 0.10 2.12 1.19 0.60 2.34
50–54 0.45 0.09 2.31 0.87 0.37 2.03
55–59 1.71 0.24 12.43 1.09 0.44 2.66
60–65 0.62 0.11 3.46 1.77 0.67 4.68
Race
Black 2.84 0.37 21.74 1.78 0.71 4.48
White 1.0 (ref) 1.0 (ref)
Other 0.64 0.23 1.78 1.75 0.81 3.79
Unknown 1.32 0.38 4.71 1.08 0.31 3.78
Family history of breast cancer
No 1.0 (ref) 1.0 (ref)
Yes 0.39 0.20 0.80 1.26 0.78 2.03
Number of prior breast biopsies
None 1.0 (ref) 1.0 (ref)
One 0.40 0.16 0.96 0.78 0.44 1.36
Two or more 0.16 0.06 0.43 0.53 0.32 0.89
Breast cancer risk
Average 1.0 (ref) 1.0 (ref)
Increased (family history of breast
cancer or personal history
of breast biopsy)
0.21 0.10 0.46 0.74 0.45 1.22
Menopausal status
Premenopausal 1.0 (ref) 1.0 (ref)
Peri- or postmenopausal 1.02 0.45 2.35 0.85 0.53 1.35
Uncertain 0.55 0.20 1.51 0.97 0.50 1.88
Estrogen use on date of exam
Nonuser or uncertain Ref Ref
Estrogen user 0.80 0.30 2.11 0.32 0.16 0.61
Charlson comorbidity index
†
0 1.0 (ref) 1.0 (ref)
1 1.68 0.63 4.50 1.75 0.99 3.04
>=2 0.48 0.20 1.15 0.70 0.37 1.31
Pap smear received on day of exam
No 1.0 (ref) 1.0 (ref)
Yes 0.97 0.48 1.96 1.06 0.48 2.31
Year of examination
1979–1982 1.0 (ref) 1.0 (ref)
‡
1983–1985 0.63 0.17 2.30 0.71 0.35 1.43
1986–1988 0.67 0.18 2.41 0.61 0.29 1.25
1989–1992 0.86 0.22 3.37 0.43 0.20 0.93
Reason for diagnostic examination
Other positive test NA 1.0 (ref)
Possibly or clearly symptomatic NA 0.81 0.49 1.33
CBE clinical breast examination, OR odds ratio, CI confidence interval.
*Odds ratios for each covariate are adjusted only for health plan. Analyses were performed with generalized estimating equations to correct standard
errors and 95% confidence intervals for clustering of examinations within women. Odds ratios less than 1.0 indicate that the factor is associated reduced
odds of a true negative examination (lower specificity). Odds ratios in bold font are statistically significant (P<0.05).
†Modified to include 1 point for hypertension.
‡P for linear trend=0.03.
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breast density (which we could not measure directly) may
affect CBE specificity independently from menopause.
12 In
addition, our study did not measure body mass index, which
has been associated with lower sensitivity of screening CBE.
9
Lastly, our study lacked detailed data on the reasons for
diagnostic examination beyond the presence of symptoms or a
previously positive test and included relatively few diagnostic
examinations among average-risk women.
Our study has several important strengths, including a
geographically diverse sample of women from 5 U.S. states
who received CBE from a range of clinical examiners. In
addition, careful ascertainment of examination purpose and
breast cancer risk factors allowed us to estimate the specificity
of both screening and diagnostic CBE and among both
average- and increased-risk women. We studied a population
receiving regular screening,
11 rather than prevalence screen-
ing as in the NBCCEDP,
7 which may provide more accurate
estimates of CBE specificity among a general population of
women receiving regular CBE screening.
Our study suggests that screening CBE in community
practice has substantially higher specificity than in clinical
trials of breast cancer screening. Diagnostic CBE, meanwhile,
is relatively nonspecific. Our findings are consistent with other
reports of high CBE specificity in unique settings
8,12 and
recent reports of low sensitivity in community practice.
7–10
Discrepant performance of CBE in the community and clinical
trials may reflect clinically important differences in examina-
tion conduct, duration, and interpretation among community
clinicians compared to highly experienced examiners in exper-
imental settings. While high specificity implies a lower risk of
false-positive CBE, this benefit may come at the cost of lower
sensitivity for breast cancer. Clinicians should try to perform
CBE in a deliberate fashion like examiners in clinical trials,
and women should be informed that a high-quality CBE may
require minutes rather than seconds.
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